Opinion/decision on a Paediatric investigation plan (PIP): (E)-4-[(5-Phenyl-1,3,4-thiadiazol-2-yl)oxy]-1-azoniatricyclo[3.3.1.13,7] decane 3,4-dicarboxy-3-hydroxybutanoate hydrate (ABT-126), decision type: , therapeutic area: , PIP number: P/0081/2014

Opinion/decision on a Paediatric investigation plan (PIP): Deucravacitinib, decision type: , therapeutic area: , PIP number: P/0286/2022

PRAC: Agendas, minutes and highlights

Human medicines European public assessment report (EPAR): Ziextenzo, pegfilgrastim, Date of authorisation: 22/11/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Breath Tests;Helicobacter Infections, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Fulphila, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Fulphila, pegfilgrastim, Neutropenia, Date of authorisation: 20/11/2018, Revision: 12, Status: Authorised

Integrilin

Human medicines European public assessment report (EPAR): Orladeyo, berotralstat, Angioedemas, Hereditary, Date of authorisation: 30/04/2021, Revision: 5, Status: Authorised